{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-004838","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2026-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.318314+00:00","generated_at":"2026-05-16T09:35:53.224240+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Dogwood Therapeutics reports Halneuron Phase 2b progress, new SP16 license, and 2026 milestones","bullets":["Over 100 patients enrolled in Halneuron Phase 2b HALT-CINP study; interim analysis determined final sample size and methodology.","Licensed SP16 IV (royalty-free, global) for cancer neuropathy; Phase 1b fully funded by NCI development grant.","Developed chemically equivalent synthetic Halneuron for Phase 3; new IP if granted extends protection to 2046.","Milestones: final Phase 2b data Q3 2026, SP16 IND filing Q1 2026, dosing Phase 1b by mid-2026.","Completed January financing (undisclosed amount) to fund pipeline; end-of-Phase 2 FDA submission targeted late 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-004838","json":"https://secwatch.observer/filing/0001104659-26-004838.json","markdown":"https://secwatch.observer/filing/0001104659-26-004838.md","text":"https://secwatch.observer/filing/0001104659-26-004838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000110465926004838/0001104659-26-004838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000110465926004838/dwtx-20260120x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:35:53.224240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}